Document Detail


Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
MedLine Citation:
PMID:  16200817     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We previously showed that H1-antihistamines may shift the PC20 (provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20%) threshold to adenosine monophosphate (AMP) challenge but may paradoxically prolong recovery. OBJECTIVES: To measure AMP recovery using a constant predetermined AMP PC20 and to evaluate whether fexofenadine use confers add-on effects to treatment with either fluticasone propionate alone or combined fluticasone propionate-salmeterol. METHODS: Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo. Recovery after a predetermined AMP PC20 challenge was measured (primary outcome), along with exhaled nitric oxide levels, plasma eosinophil cationic protein levels, peripheral eosinophil counts, pulmonary function, diary card outcomes, and quality of life (all secondary outcomes). RESULTS: There were no differences in any of the primary or secondary outcomes when fexofenadine was added to treatment with either fluticasone propionate-salmeterol or fluticasone propionate alone. The mean AMP recovery time was 25.0 vs 23.4 minutes for fexofenadine and placebo, respectively, as add-on to fluticasone-salmeterol and 22.5 vs 23.9 minutes, respectively, as add-on to fluticasone alone. CONCLUSION: Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treatedatopic asthmatic patients.
Authors:
Tom C Fardon; Daniel K C Lee; Melissa R Hodge; Brian J Lipworth
Related Documents :
20926507 - The relationship between gastroesophageal reflux and asthma: an update.
16701667 - Clinicians tend to overestimate improvements in asthma control: an unexpected observation.
11716197 - The role of the asthma nurse in treatment compliance and self-management following hosp...
14730657 - Efficacy and safety of formoterol turbuhaler when added to inhaled corticosteroid treat...
1852157 - Involvement of thin afferents in carpal tunnel syndrome: evaluated quantitatively by ar...
14499767 - Endoscopic implantation of enteryx for treatment of gerd: 12-month results of a prospec...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  95     ISSN:  1081-1206     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-10-04     Completed Date:  2005-10-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  259-65     Citation Subset:  IM    
Affiliation:
Asthma and Allergy Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Monophosphate / immunology
Administration, Inhalation
Adolescent
Adrenal Cortex Hormones / administration & dosage*
Adult
Albuterol / analogs & derivatives,  therapeutic use
Androstadienes / therapeutic use
Anti-Allergic Agents / therapeutic use*
Asthma / drug therapy*
Biological Markers
Bronchial Provocation Tests
Drug Therapy, Combination
Eosinophil Cationic Protein / blood,  drug effects
Eosinophils / drug effects
Female
Humans
Hypersensitivity, Immediate / drug therapy*
Inflammation / immunology
Male
Nitric Oxide / analysis
Respiratory Function Tests
Terfenadine / analogs & derivatives*,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Androstadienes; 0/Anti-Allergic Agents; 0/Biological Markers; 10102-43-9/Nitric Oxide; 138452-21-8/fexofenadine; 18559-94-9/Albuterol; 50679-08-8/Terfenadine; 61-19-8/Adenosine Monophosphate; 89365-50-4/salmeterol; 90566-53-3/fluticasone; EC 3.1.27.-/Eosinophil Cationic Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years.
Next Document:  Analysis of vascular endothelial growth factor levels in induced sputum samples from patients with c...